



**I-MAB**  
BIOPHARMA

## **I-Mab Confirms No Banking Relationship with Silicon Valley Bank**

March 13, 2023

In light of the recent development of the Silicon Valley Bank (the “SVB”), I-Mab (the “Company”) today issued a statement confirming that the Company does not hold any cash deposits at SVB or its affiliates, and has no exposure to or business dealings with SVB or its affiliates.

### **About I-Mab**

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit <https://www.i-mabbiopharma.com> and follow I-Mab on [LinkedIn](#), [Twitter](#), and [WeChat](#).